Akero Therapeutics, Inc.

Altimmune highlighted a broad range of target indications for its “pipeline-in-a-product” candidate pemvidutide in a 13 March R&D Day presentation for investors and analysts that could expand the

Fundraising by biopharmaceutical companies surged in 2024 to $86.67bn, up 16.2% from $74.59bn in 2023, according to data collected by Biomedtracker. The good fortune was shared across both public and

In the highly competitive race to follow Madrigal to market in metabolic dysfunction-associated steatohepatitis (MASH), perhaps the two most closely watched drug classes are the GLP-1 agonists, which

Madrigal’s successful launch of its metabolic dysfunction-associated steatohepatitis (MASH) drug Rezdiffra (resmetirom) continued during the fourth quarter and on 26 February the company predicted str